Background: Designing biologically informative models for assessing the safety of
| INTRODUCTION
Differences between species render the mouse system inadequately representative of human IgE biology. These include the absence of human IgE binding to murine FceRs 4, 5 and differential FceRI structure (murine FceRI is tetrameric, while human FceRI exists both as a tetramer and a trimer). 4 Murine FceRIs are expressed solely on mast cells and basophils, 4 whereas in rats, similar to humans, expression is on mast cells, basophils, eosinophils, monocytes and macrophages. 6, 7 These features suggest the rat, rather than the mouse, as a model immune system better suited to preclinical evaluations of human IgE.
We previously reported the in vivo efficacy of recombinant chimeric (mouse/human) antibody, hMOv18 IgE, specific for the human tumour-associated antigen folate receptor a (FRa), overexpressed in solid tumours including ovarian carcinomas. The antitumour activity of hMOv18 IgE was superior to the equivalent hMOv18 IgG in a syngeneic rat model, and in two human ovarian carcinoma xenograft mouse models reconstituted with human immune cells. [8] [9] [10] [11] [12] In preparation for a clinical trial of hMOv18 IgE, we hypothesized that an immunocompetent rat model would provide the most comprehensive evaluation of safety and efficacy. This model was selected because it provides i) a species in which the native FceR is expressed on effector cell populations similar to human cells, ii) an opportunity to study syngeneic tumours in highly vascularized lungs of immunocompetent animals, iii) a self-replenishing supply of native effector cells and iv) a chance to evaluate antibody safety in the presence of antitumour IgE-mediated responses in tumour-bearing animals.
11
Although human exposure to exogenous IgE has been reported, 13 
| Generation of anti-FRa antibodies with human and rat Fc regions
Chimeric mouse/human antibodies, hMOv18 IgE and IgG1 were prepared as before. 8 Chimeric mouse/rat rMOv18 IgE and IgG2b were designed with rat constant and mouse variable domains specific for human FRa ( Figure 1A ). Heavy and light chain region sequences were cloned into single mammalian expression vectors containing a hygromycin resistance gene (pVITRO1) 15 and transfected into FreeStyle TM 293-F cells. Selected rMOv18 IgE-and IgG2b-transfected cells were expanded using an AppliFlex Single-Use Bioreactor (Applikon Biotechnology) (50L bioreactor wave bag, 25L working volume).
G R A P H I C A L A B S T R A C T
To study IgE class-specific functions and safety, we designed a surrogate rat tumour model and rat equivalent antibodies of a human/chimeric (Table S1A ). Signs of anaphylaxis were evaluated using a previously described anaphylactic scoring system 18 (Table S1B ).
| Clinical pathology
Blood samples were drawn into EDTA and lithium heparin collection tubes and analysed for haemoglobin concentration, total white blood cell count, neutrophil count, and creatinine, alanine aminotransferase and aspartate aminotransferase concentrations (haematological parameters: ADVIA 120 haematology analyser; biochemistry parameters: Roche Modular Evo (P800) clinical chemistry analyser). Full necropsies were performed at day 30 following tumour challenge. Tissues were preserved in neutral buffered formaldehyde before processing for histological evaluation.
| Histological evaluations
Rat tissues (thymus, injection site (tail), spleen, lymph nodes, liver, kidney, lungs, colon and brain) were submerged in neutral buffered formaldehyde, embedded in paraffin wax, cut at a nominal thickness of 4-5 lm, stained with haematoxylin and eosin and analysed on a Zeiss Axiophot microscope (910, 920 magnification lenses, Carl Zeiss) and NIS Elements imaging software (Nikon).
| Statistical methods
Parametrically distributed data were compared with an unpaired two-tailed Student's t test. Nonparametric data were compared using the Mann-Whitney U test. All statistical analyses were performed using GraphPad TM Prism software (version 5.03, GraphPad TM ). P values were represented as follows: *P < .05, **P < .01, ***P < .001, ****P < . 
| RESULTS

| Generation and receptor-binding characteristics of rat MOv18 IgE and IgG2b
We generated anti-human FRa mouse/rat chimeric (mouse variable/ rat constant domains) rMOv18 IgE and IgG2b, surrogates of the original mouse/human chimeric hMOv18 IgE and IgG1, respectively. Rat
IgG2b isotype was chosen as equivalent to mouse IgG2a/b and human IgG1, based on complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC) functions ( Figure 1A ). 19 Variable region DNA sequences for the MOv18 epitope on human FRa were combined with rat immunoglobulin constant region DNA sequences. The complete heavy and light chains of each rMOv18
IgE and IgG2b antibody ( Figure 1A ) were synthesized using GeneArt Gene Synthesis. Antibody chains were cloned within a dual antibody expression cassette into a single mammalian expression vector (pVI-TRO1), by employing an adapted and optimized Polymerase Incomplete Primer Extension (PIPE) cloning method that allowed seamless assembly of multiple DNA fragments. 15 The pVITRO-Rat MOv18 IgE and pVITRO-Rat MOv18 IgG2b vectors ( Figure 1B ) contained a hygromycin B resistance gene, enabling antibiotic selection of transfected FreeStyle TM 293-F cells. Semistable cell lines were generated for large-scale antibody production.
As no universal purification method exists for rat IgE, 20 we designed a strategy using a mixed-mode chromatography resin, IgE was eluted using a 25% isopropanol elution buffer, and SDS-PAGE revealed strong bands at the expected molecular weight (200 kDa for rat IgE) 22 ( Figure 1C ). Following HPLC purification, human and rat MOv18 IgE (180 and 260 kDa) and MOv18 IgG (160 kDa) appeared as single bands, 22 corresponding to expected antibody molecular weights ( Figure 1D ). HPLC-SEC elution profiles confirmed the generation of monomeric antibodies of purity >85%
( Figure 1E ). 
| Establishment of a tumour-bearing surrogate rat model to interrogate IgE functions
Folate receptor a expression is reported to be absent or lowly expressed in normal tissues, 23 
| Safety of rat MOv18 IgE and IgG2b in vivo
We interrogated the rat model with respect to safety using scoring criteria previously described to evaluate general toxicities in rodents (Table S1A ) and in vivo anaphylactic responses (Table S1B) . 17, 18 We also conducted histopathological evaluations of several organs to detect tissue damage, especially from immunological infiltration or tissue remodelling.
Safety evaluations of rMOv18 IgE were conducted at weekly doses of 5, 10 and 50 mg/kg and compared with rMOv18 IgG2b
and PBS. Buffer alone-treated rats demonstrated a single toxicity of subdued but responsive behaviour (69%, mild score; Table S2 ).
Of the possible general and anaphylactic toxicities, only 3 categories were observed in rats treated with rMOv18 IgE or IgG2b.
These were as follows: subdued but responsive behaviour; piloerection; and hunching. All toxicities were scored as mild only, occurred immediately upon waking from anaesthetic, and lasted for 10-15 minutes thereafter. Severity was similar for both IgEand IgG2b-treated rats (Table S2 , Figure 3A) . Additionally, the number of toxicities experienced by each animal in each treatment group was similar between the IgE-and IgG-treated groups at each dose ( Figure 3B ). None of the rats in any treatment group experienced any symptom that would constitute an anaphylactic response, according to a published anaphylaxis scoring system (Table S1B) . 18 Histopathological evaluations of several tissues were conducted to determine potential off-target toxicities. No obvious pathological lesions associated with 5 or 50 mg/kg IgE, or IgG2b administration, were detected in major physiological systems (spleen, lymph nodes, liver, kidney, colon, brain) ( Figure 3C ). IgE administration had no effect on body weight ( Figure 4A ), serum blood chemistry or haematological parameters (creatinine, liver transaminases, haemoglobin and white blood cell counts) compared with PBS treatment (Figure 4B-E ten rats treated with 10 mg/kg and in the serum of one of ten rats treated with 50 mg/kg IgE ( Figure 4F-G) .
We concluded that administration of rMOv18 IgE to tumour-bearing rats induced no clinical, histopathological or metabolic signs of a type I hypersensitivity reaction, even at weekly 50 mg/kg doses. We generated mRNA expression profiles from tumour-bearing rat lungs excised from animals treated with PBS or rMOv18 IgE. We Figure 5F ). , hunching and reduced activity) . B, Percentage of animals within each treatment group to experience 1, 2 or 3 toxicities. C, Histopathological evaluations of tissues 30 days after administration of two doses (every 14 days) of rMOv18 IgE or IgG2b at 5 mg/kg and 50 mg/kg or PBS rats (n = 10 per group). Sections were stained with H&E and observed at brain = 25 9 magnification; colon, kidney, liver, mesenteric lymph nodes (LN), tail and thymus = 50 9 magnification; spleen = 100 9 magnification [Colour figure can be viewed at wileyonlinelibrary.com] F I G U R E 4 Absence of rMOv18 IgE-associated changes in body weight or blood haematological or biochemical parameters. A, Weekly weights of rats following weekly treatment with rMOv18 IgE at 1 mg/kg (n = 10), 10 mg/kg (n = 10) and 50 mg/kg (n = 10) or PBS (n = 10). B-E, Blood biochemical and haematological parameters were measured immediately before necropsy on day 30 following 4 weekly doses of rMOv18 IgE at 1 mg/kg (n = 10), 10 mg/kg (n = 10) and 50 mg/kg (n = 10) or PBS (n = 10). We previously reported that TNFa-expressing mature macrophage subsets infiltrated tumour lesions and that elevated levels of TNFa were detected in lungs of rMOv18 IgE-treated rats compared with controls. 11 Here, we also observed significantly elevated circulating TNFa in IgE-treated compared with PBS-treated rats (P = .0044) ( Figure 6A-B) . 11 Previously, we found elevated macrophage chemoattractant protein-1 (MCP-1) in the lung environment of IgE-treated animals potentiated by local upregulation of TNFa following IgE cross-linking on tumour-associated macrophages. Here, we measured detectable serum MCP-1 in IgE-treated rats, but these were not significantly elevated compared with controls ( Figure 6C ).
| Immune cell infiltration and immune activation signatures associated with MOv18 IgE in vivo
On the other hand, concentrations of the classical "cytokine storm"-related cytokines IL-6 and IFN-c were undetectable in rat sera from all groups. Furthermore, concentrations of IL-4, a key cytokine in the development of allergic inflammation, were undetectable in sera of IgE-treated and PBS-treated rats ( Figure 6D ). These data are consistent with more prominent activation of immune cascades locally in tumours rather than systemically.
Together these findings point to immune cell recruitment, and activation of immunological pathways and mediators associated with We completed the rat model by generating surrogate rat IgE and
IgG. We present a simple process for cloning heavy and light chains of any antibody clone into a single mammalian expression vector and report serum-free production by mammalian cells by scale-up in bioreactors. These processes are easily adaptable for generating antibodies of any isotype or specificity. Furthermore, the only currently reported purification method for monoclonal rat IgE is for a dinitrophenyl-specific rat IgE (DNP IgE), purified by an affinity column based on antigen specificity. 20 By contrast, our purification process for rat IgE regardless of antigen specificity using HCIC is also applicable for human IgE purification. Engineering, cloning and purification of intact, functional
IgE of sufficient purity and yield for in vivo studies reported in the design of this rat model represents a methodology applicable to the generation of IgE and IgG antibodies of any specificity and species.
Administration of rMOv18 IgE and IgG2b to tumour-bearing rats demonstrated only three toxicities, observed with both isotypes.
Accordingly, none of the anaphylaxis-specific toxicities detailed in previously published criteria 18 were detected with any treatment.
Moreover, immunohistochemical toxicity studies on several tissues from IgE-, IgG2b-and PBS-treated rats revealed no evidence of pathological lesions, even at weekly 50 mg/kg antibody doses.
Together with our previously published data, these findings support clinical systemic MOv18 IgE administration. 14 We previously reported that human IgE cross-linked on the surface of human monocytes triggered monocyte activation and TNFa upregulation; furthermore, human IgE antitumour ADCC was associated with enhanced TNFa. In parallel, we detected TNFaexpressing macrophage subsets and elevated concentrations of 
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